Cancer is the most lethal disease and finding its potential treatment is the biggest challenge for the scientists. The major hindrance in cancer research is the requirement of funds. Recently, the University of Toledo got a huge fund by Susan G. Komen of Northwest Ohio for a cutting-edge research to find novel treatments for a very aggressive and recurring Triple Negative Breast Cancer (TNBC). Research depicts about 15% of the breast cancer to be TNBC affecting younger people more.
Dr. Amit Tiwari, an Assistant Professor in the College of Pharmacy in UT has discovered a promising new drug for Triple Negative Breast Cancer where patients resist conventional chemotherapy. He opines that cancer cells should be targeted in a non-conventional way in order to overcome multi-drug resistance and increase survival rates. In this regard, drug-resistant factors must be targeted along with Triple Negative Breast Cancer with specially designed and developed molecules.
The research will soon reach clinical trials and benefit patients in about 3-5 years due to generous funding by Komen. Dr. Tiwari is working with his team of graduate students in which a member from Rwanda, Angelique Nyinawabera stated that what keeps her morale high for the research is the struggle by her close people in fighting cancer and the breast patients should know for sure that the scientists are fighting along with them to come up with a cure.
Dr. Tiwari highly acknowledged the investment by Komen by stating that words cure and cancer were heard due to such research funds. He further expressed that there were few obstacles and challenges in the research but they were soon going to find a cure as cancer is absolutely treatable. More money could help reach the clinical trials in less than two years for which people should take part in the races for the cure!